lyophilized powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-31. Anything still debated is marked as such rather than presented as settled.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Identity and purity are assessed with a small set of standard peptide methods. Reversed-phase high-performance liquid chromatography separates the main peak from truncated or oxidized species, and its area percentage is the usual purity measure. Mass spectrometry confirms the observed molecular mass against the expected value, while amino acid analysis or peptide mapping checks composition and sequence. Specifications for research-grade material are often stated as 95 percent or higher, though the exact limit depends on the supplier and the intended use.
Laboratory supplies of the peptide usually arrive as a lyophilized powder in sealed vials. The powder is hygroscopic, so a vial should be allowed to reach room temperature before it is opened to prevent condensation on the contents. Weighing and transfer are best performed in a low-humidity environment with clean tools. Once dissolved, the solution should be mixed gently rather than vortexed, because foaming and shear can reduce recovery of the peptide.
==== Gel particle synthesis ==== The synthesis of gel particles also known as hydrogels, microgels, and nanogels, has been an area of interest for researchers and industries alike for the last several decades. A microfluidic based approach to synthesizing these hydrogel particles is a useful tool, due to high throughput, mono-dispersity of particles, and cost reduction through the use of small reagent volumes. One of the key challenges early on in the field of gels was forming monodisperse particles. Initially polymerization-based techniques were used to form bulk microparticles that were polydisperse in size. These techniques generally were centered around using an aqueous solution that was mixed vigorously to create emulsions. Eventually a technique was developed to create monodisperse biodegradable microgels by making O/W emulsions in an in-line droplet generating channel geometry. This junction geometry accompanied with a surfactant laden continuous phase was responsible for creating microgels made from poly-dex-HEMA. Other device geometries including T-junction style formation are also viable and have been used to make silica-based gels. Once these methods were established, efforts focused on applying functionality to these particles. Examples include bacteria encapsulated particles, drug or protein encapsulated particles, and magnetic gel particles. To insert these functional components into the gel structure, can be as simple as integrating the component into the dispersed phase.
=== Phosphoenolpyruvate carboxykinase (PEPC-K) === Glyceroneogenesis can be regulated at two reaction pathways. First, it can be held at the decarboxylation of oxaloacetate to phosphoenolpyruvate. Secondly, the TCA cycle can affect glyceroneogenesis when the glutamate or substrates in the TCA cycle are being used as a precursor. Decarboxylation of oxaloacetate to phosphoenolpyruvate is catalyzed by PEPC-K, the essential enzyme which regulates glyceroneogenesis. Increases in PEPC-K levels or overexpression of the gene that codes for PEPC-K will increase glyceroneogenesis. Also, oxaloacetate can be decarboxylated to phosphoenolpyruvate when more PEPC-K can catalyze the reaction. Gene expression of PEPC-K can be suppressed by norepinephrine, glucocorticoids, and insulin. Norepinephrine is a neurotransmitter which decreases the activity of PEPC-K when the cell is in a cold environment. Glucocorticoids are steroid hormones involved in the reciprocal regulation of glyceroneogenesis in the liver and adipose tissues. Through a poorly-understood mechanism, they induce transcription of PEPC-K in the liver while decreasing transcription in adipose tissues. Insulin is a peptide hormone that causes cells to take in glucose. Through glyceroneogenesis, insulin down-regulates the expression of PEPC-K in both liver and adipose tissues.
In October 2024, Save the Children reported that of the approximately 3000 under five-years-old children they had screened, about 20 percent had moderate acute malnutrition and four percent had severe acute malnutrition. From 2 March until 26 May 2025, Israel completely blocked all supplies from entering Gaza, making it the longest complete closure in the history of the blockade. Since 26 May 2025, the United States- and Israeli-backed Gaza Humanitarian Foundation has facilitated limited and largely ineffective aid distribution. In June 2025, UNICEF-supported clinics in Gaza reported a sharp rise in child malnutrition: 16,736 children were treated between January and May 2025, including 5,119 in May alone. This was nearly 50% more than in April and over double the February figure. Of these, 636 had severe acute malnutrition, the deadliest form, which has risen by about 146% since February. UNICEF warns that without large-scale aid deliveries, acute malnutrition could reach its highest level since the conflict began, despite wasting being virtually absent 20 months earlier.
For cases of recurrent pericardial effusion, an operation to create a hole between the pericardial and pleural spaces can be performed, known as a pericardial window or pericardiostomy. The congenital absence of pericardium is rare. When it happens, it usually occurs on the left side. Those affected usually do not have any symptoms and they are usually discovered incidentally. About 30 to 50 percent of the affected people have other heart abnormalities such as atrial septal defect, patent ductus arteriosus, bicuspid aortic valve, and lung abnormalities. On chest X–ray, the heart looks posteriorly rotated. Another feature is the sharp delineation of pulmonary artery and transverse aorta due to lung deposition between these two structures. If there is partial absence of pericardium, there will be bulge of the left atrial appendage. On CT and MRI scans, similar findings as chest X–ray can be shown. The left sided partial pericardium defect is difficult to see because even a normal pericardium is difficult to be seen on CT and MRI. A complete pericardial defect will show the heart displaced to the left with part of the lungs squeezed between inferior border of heart and diaphragm.
Regulation of e-cigarettes varies across countries and states, ranging from no regulation to banning them entirely. For instance, e-cigarettes containing nicotine are illegal in Japan, forcing the market to use heated tobacco products for cigarette alternatives. Others have introduced strict restrictions and some have licensed devices as medicines such as in the UK. However, as of February 2025, there is no e-cigarette device that has been given a medical license that is commercially sold or available by prescription in the UK. As of 2015, around two thirds of major nations have regulated e-cigarettes in some way. Because of the potential relationship with tobacco laws and medical drug policies, e-cigarette legislation is being debated in many countries. The companies that make e-cigarettes have been pushing for laws that support their interests. In 2016 the US Department of Transportation banned the use of e-cigarettes on commercial flights. This regulation applies to all flights to and from the US. In 2018, the Royal College of Physicians asked that a balance is found in regulations over e-cigarettes that ensure product safety while encouraging smokers to use them instead of tobacco, as well as keep an eye on any effects contrary to the control agencies for tobacco. The legal status of e-cigarettes is currently pending in many countries. Many countries such as Brazil, Singapore, Uruguay, and India have banned e-cigarettes. In June 2025, Pakistan banned e-cigarettes in the province of Punjab, though the decision was reversed the next month.
Sources: en.wikipedia.org
=== Homo erectus === At the beginning of the Paleolithic, hominins were found primarily in eastern Africa, east of the Great Rift Valley. Most known hominin fossils dating earlier than one million years before present are found in this area, particularly in Kenya, Tanzania, and Ethiopia. By c. 2,000,000 – c. 1,500,000 BP, groups of hominins began leaving Africa, settling southern Europe and Asia. The South Caucasus was occupied by c. 1,700,000 BP, and northern China was reached by c. 1,660,000 BP. By the end of the Lower Paleolithic, members of the hominin family were living in what is now China, western Indonesia, and, in Europe, around the Mediterranean and as far north as England, France, southern Germany, and Bulgaria. Their further northward expansion may have been limited by the lack of control of fire: studies of cave settlements in Europe indicate no regular use of fire prior to c. 400,000 – c. 300,000 BP. East Asian fossils from this period are typically placed in the genus Homo erectus. Very little fossil evidence is available at known Lower Paleolithic sites in Europe, but it is believed that hominins who inhabited these sites were likewise Homo erectus. There is no evidence of hominins in America, Australia, or almost anywhere in Oceania during this time period. Fates of these early colonists, and their relationships to modern humans, are still subject to debate. According to current archaeological and genetic models, there were at least two notable expansion events subsequent to peopling of Eurasia c. 2,000,000 – c. 1,500,000 BP.
Fast (rotary) potters' wheels enabled early mass production of pottery, but it was the use of the wheel as a transformer of energy (through water wheels, windmills, and even treadmills) that revolutionized the application of nonhuman power sources. The first two-wheeled carts were derived from travois and were first used in Mesopotamia and Iran around 3,000 BCE.
Arab immigration to Venezuela started as early as the 19th and 20th centuries, with migrants primarily hailing from the Ottoman provinces of Lebanon, Syria, and Palestine. They settled predominantly in Caracas, and have significantly influenced Venezuelan culture, particularly in terms of Arabic food and music. Religiously, the Arab-Venezuelans community consists mainly of Druze and Christians, who are affiliated with the Roman Catholic, Eastern Orthodox and Eastern Rite Catholic Churches. Venezuela hosts the largest Druze communities outside the Middle East, estimated at around 60,000 individuals. Most of them trace their ancestry back to Lebanon and Syria. More than 200,000 people from the As-Suwayda area hold Venezuelan citizenship, the majority of whom belong to the Syria's Druze sect and immigrated to Venezuela in the past century. The early Druze migrants to Venezuela assimilated well into the local population, with some even converting Catholicism. Nevertheless, many retained a strong Druze and Arab identity, along with adherence to Druze values. A prominent example of Druze influence in this Catholic country is the former vice president, Tareck El Aissami, who is of Druze descent. Other notable Venezuelan figures of Druze origin include Haifa El Aissami and Tarek William Saab.
Food Administration International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) African Union: African Medicines Agency Australia: Therapeutic Goods Administration Brazil: National Health Surveillance Agency Canada: Marketed Health Products Directorate Canada: Health Canada Denmark: Danish Medicines Agency European Union: European Food Safety Authority and European Medicines Agency Germany: Federal Institute for Drugs and Medical Devices India: Food Safety and Standards Authority of India and Central Drugs Standard Control Organization Japan: Ministry of Health, Labour and Welfare (MHLW) Japan: Pharmaceuticals and Medical Devices Agency Mexico: Federal Commission for the Protection against Sanitary Risk Philippines: Food and Drug Administration (FDA) Singapore: Health Sciences Authority United Kingdom: Food Standards Agency and Medicines and Healthcare products Regulatory Agency
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
Cool storage below freezing is usual for long-term retention, with a desiccant and protection from light. Portions are often split before first use to avoid repeated handling.
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.